Molecular mimicry of human tRNA^{Lys} anti-codon domain by HIV-1 RNA genome facilitates tRNA primer annealing

CHRISTOPHER P. JONES,^{1,3} JENAN SAADATMAND,^{2,3} LAWRENCE KLEIMAN,² and KARIN MUSIER-FORSYTH^{1,4}

¹Department of Chemistry and Biochemistry, Center for Retroviral Research, and Center for RNA Biology, The Ohio State University, Columbus, Ohio 43210, USA

²Lady Davis Institute for Medical Research, McGill AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada, H3T1E2

ABSTRACT

The primer for initiating reverse transcription in human immunodeficiency virus type 1 (HIV-1) is tRNA^{Lys3}. Host cell tRNA^{Lys} is selectively packaged into HIV-1 through a specific interaction between the major tRNA^{Lys}-binding protein, human lysyl-tRNA synthetase (hLysRS), and the viral proteins Gag and GagPol. Annealing of the tRNA primer onto the complementary primer-binding site (PBS) in viral RNA is mediated by the nucleocapsid domain of Gag. The mechanism by which tRNA^{Lys3} is targeted to the PBS and released from hLysRS prior to annealing is unknown. Here, we show that hLysRS specifically binds to a tRNA anti-codon-like element (TLE) in the HIV-1 genome, which mimics the anti-codon loop of tRNA^{Lys} and is located proximal to the PBS. Mutation of the U-rich sequence within the TLE attenuates binding of hLysRS in vitro and reduces the amount of annealed tRNA^{Lys3} in virions. Thus, LysRS binds specifically to the TLE, which is part of a larger LysRS binding domain in the viral RNA that includes elements of the Psi packaging signal. Our results suggest that HIV-1 uses molecular mimicry of the anti-codon of tRNA^{Lys} to increase the efficiency of tRNA^{Lys3} annealing to viral RNA.

Keywords: tRNA anti-codon-like element; lysyl-tRNA synthetase; reverse transcription; primer placement

INTRODUCTION

Transfer RNAs are the adaptor molecules in protein synthesis, binding trinucleotide codons through specific base-pairing interactions and translating them into the amino acid sequence of proteins. They accomplish this by delivering specific amino acids, which are covalently attached to their 3' ends by aminoacyl-tRNA synthetases. In addition to their central role in protein biosynthesis, tRNAs and tRNA-like elements are used for a variety of cellular roles and are exploited by viruses in their replication (Dreher 2009). For example, plant viruses contain tRNA anti-codon-like elements (TLEs) at their 3' ends that are bound by aminoacyl-tRNA synthetases and aminoacylated (Dreher 2009; Hammond et al. 2009). The solution structure of a portion of the 3' UTR of turnip crinkle virus has structural features that resemble those of a

tRNA (Hammond et al. 2009), the pea enation mosaic virus has been predicted to contain a T-shaped tRNA-like structure (Gao et al. 2012), and the intergenic region of cricket paralysis virus also mimics the tRNA structure to enhance its own translation (Costantino et al. 2008).

Many retroelements and all retroviruses, including human immunodeficiency virus type 1 (HIV-1) initiate reverse transcription of their viral RNA genome (vRNA) from the 3' end of a host cellular tRNA (Coffin et al. 1997). Human tRNA^{Lys3} is the primer for HIV-1 and is selectively packaged into the virus along with the other major tRNA^{Lys} isoacceptors in the cell, tRNA^{Lys1} and tRNA^{Lys2} (Jiang et al. 1993; Pavon-Eternod et al. 2010). Upon virus entry into target cells, the single-stranded vRNA is reverse transcribed into double-stranded proviral DNA, which is integrated into host DNA. Following export from the nucleus, newly synthesized vRNA, viral precursor proteins Gag and GagPol, and other cellular factors co-opted by the virus assemble at a cytoplasmic site prior to viral budding. While the processing of the major HIV-1 precursor proteins Gag and GagPol into mature viral proteins occurs during and after viral budding from the cell, annealing of tRNA^{Lys3} to vRNA occurs in the absence of precursor protein processing (Huang et al. 1997). The selective incorporation of primer tRNA^{Lys3} is required for optimizing both tRNA^{Lys3} annealing to the viral RNA primer binding site (PBS) and viral infectivity of the HIV-1 population (Gabor et al. 2002). The cytoplasmic nucleoprotein complex

³These authors contributed equally to this work.

Abbreviations: HIV-1, human immunodeficiency virus type 1; TLE, tRNA anti-codon-like element; hLysRS, human lysyl-tRNA synthetase; hLysRSΔN65, hLysRS lacking N-terminal 65 amino acids; LysRS-BD, LysRS binding domain; ProRS, prolyl-tRNA synthetase; TrpRS, tryptophanyl-tRNA synthetase; UTR, untranslated region; WT, wild-type; nt, nucleotide(s); vRNA, viral RNA; RSV, Rous sarcoma virus; IRES, internal ribosome entry site; PBS, primer binding site; EMSA, electrophoretic mobility shift assay

⁴Corresponding author

E-mail musier@chemistry.ohio-state.edu

Article published online ahead of print. Article and publication date are at <http://www.rnajournal.org/cgi/doi/10.1261/rna.036681.112>.

into which tRNA^{Lys3} is recruited prior to PBS annealing also includes human lysyl-tRNA synthetase (hLysRS), Gag, GagPol, and vRNA (Kleiman et al. 2010). The selective incorporation of tRNA^{Lys} isoacceptors appears to be due to a specific interaction between Gag and hLysRS (Javanbakht et al. 2003; Kovaleski et al. 2007). GagPol is also required for binding to tRNA^{Lys} and facilitating its incorporation (Khorchid et al. 2000; Kobbi et al. 2011), and an interaction between hLysRS and Pol has been proposed (Saadatmand et al. 2008; Kobbi et al. 2011).

Human tRNA^{Lys} and hLysRS are both present in 20–25 molecules per virion and are likely packaged into virions as a complex (Huang et al. 1994; Cen et al. 2002). The relative level of packaged tRNA^{Lys} is linked to both packaged LysRS and virus infectivity; that is, knockdown of cytoplasmic hLysRS reduces the amount of tRNA^{Lys} in the virus and subsequently reduces virus infectivity, whereas overexpression of hLysRS causes the opposite effect (Guo et al. 2003, 2005). The selective incorporation of tRNA^{Lys} into virions may also reflect a higher concentration of tRNA^{Lys} at the cellular site of HIV-1 assembly or alterations to the tRNA pool induced by HIV-1 infection (van Weringh et al. 2011; Li et al. 2012).

Although the ~9.4-kB vRNA contains secondary structural elements whose functions are, in most cases, still unknown (Watts et al. 2009), the 5′ untranslated region (UTR) is especially rich in complex secondary structures with known functions in many steps of the virus life cycle (Coffin et al. 1997; Bolinger and Boris-Lawrie 2009). For example, Gag facilitates tRNA^{Lys3} primer annealing onto a highly conserved sequence in the 5′ UTR (Feng et al. 1999; Roldan et al. 2005; Jones et al. 2011). The longest motif in this sequence, the 18-nt PBS is complementary to the 3′ 18-nt of tRNA^{Lys3}. Additional interactions occur between vRNA and complementary sequences in the variable arm and anti-codon stem-loop of tRNA^{Lys3} (Isel et al. 1993; Arts et al. 1996; Beerens et al. 2001; Iwatani et al. 2003; Wilkinson et al. 2008).

An essential component of the translation machinery, hLysRS binds to tRNA^{Lys} through specific interactions with its anti-codon binding domain (Stello et al. 1999) and less specific interactions via an N-terminal extension (Francin et al. 2002; Francin and Mirande 2006). Mammalian LysRS binds its tRNA substrates with high affinity (Francin et al. 2002), and the mechanism of tRNA^{Lys3} release from hLysRS and targeting to the PBS during formation of the annealing complex is presently unknown. This is an important question since only a limited number of Gag-GagPol complexes are expected to be bound to hLysRS/tRNA^{Lys3}, and only two copies of vRNA are packaged per virion. Thus, a mechanism for increasing the likelihood that the tRNA^{Lys}-containing complexes bind proximal to the PBS may be beneficial to the virus. In this work, we provide evidence that a tRNA^{Lys} anti-codon-like sequence in the vRNA located near the PBS can interact with hLysRS, and we discuss possible roles for tRNA mimicry in initiation complex formation and HIV-1 replication.

RESULTS

HIV-1 genome contains a tRNA^{Lys} anti-codon-like element

Using a recent secondary structural model of the HIV-1 vRNA (Watts et al. 2009), we searched for tRNA^{Lys3}-like secondary structural elements proximal to the PBS. A hairpin containing a loop sequence resembling the anti-codon loop of tRNA^{Lys3} was identified directly upstream of the PBS (Fig. 1A, TLE, boxed). We examined the conservation of the tRNA anti-codon-like element across ~2170 HIV-1 isolates (Fig. 2; Methods in Supplemental Material). The center U nucleotide in the loop, corresponding to U35 in tRNA^{Lys3}, is 95% conserved. Anti-codon positions U35 and U36 are identity elements critical for tRNA^{Lys3} binding and aminoacylation by hLysRS in vitro (Stello et al. 1999) and in vivo (Javanbakht et al. 2002). Point mutations at position 35 have the most severe effects on hLysRS catalytic efficiency (ranging from ~150-fold to >3000-fold reduction of k_{cat}/K_M) (Stello et al. 1999). Thus, the high conservation of the central U in the TLE loop is consistent with a favorable hLysRS binding site.

To further examine the conservation of the viral genome TLE loop sequences across HIV-1 isolates, we divided sequences by virus subtype or clade (described in Supplemental Material, Methods). Most of the sequences originate from clades B and C, which represent the majority of infections in the Americas, Europe, Asia, and South and East Africa (Coffin et al. 1997). Alignment of TLE loop nucleotides from clades B and C demonstrates that in these viruses, the TLE is U-rich (Supplemental Fig. S1) and is highly conserved, especially among clade B viruses (Fig. 2). In contrast, viruses from other clades—including clades A and G and recombinant forms of these clades—contain a central U flanked by two C nucleotides (Supplemental Fig. S1). This variation contributes to the lower conservation in the nucleotides surrounding the highly conserved U154 when all clades are included in the alignment (Fig. 2). Structure-probing studies of HXB2 (a clade B isolate) and MAL (a mosaic of clades A, D, and I) concluded that the two viruses have different PBS stem folds (Goldschmidt et al. 2004). In HXB2, the U-rich anti-codon-like element is an exposed 7-nt loop (Fig. 1A), as found in previous structure probing of the clade B HIV-1 LAI strain (Damgaard et al. 1998). In the MAL isolate, an alternative 6-nt A-rich apical loop is formed (Fig. 1C). The CUC triplet corresponding to the clade B UUU triplet is located in the base-paired stem region (Goldschmidt et al. 2004). In this work, we examine TLE sequences from a clade B virus, NL4-3, as well as an RNA derived from the MAL isolate (Fig. 1).

hLysRS specifically binds viral TLE-containing RNAs

Electrophoretic mobility shift assays (EMSAs) were carried out to determine if hLysRS could bind to a 105-nt segment

FIGURE 1. (A) Predicted secondary structure of a 329-nt RNA derived from the HIV-1 NL4-3 5' UTR with the TLE sequence boxed and PBS circled and in bold. Although only the TLE loop sequence resembles the anti-codon domain of tRNA^{Lys3}, we have included the flanking 3-bp stem domain in our definition of the TLE to emphasize the presentation of anti-codon-like nucleotides in an exposed loop. The NL4-3 "PBS/TLE" RNA used in this study (105 nt) contains nt 125–223 plus three additional 5'-G-C-3' pairs to stabilize the terminal RNA stem and aid in vitro transcription. The 330-nt 5' UTR RNA used in this study contains the 329-nt sequence shown with an additional 5'-G residue for in vitro transcription. The ΔTARpolyA mutation is a deletion of nt 1–124, the ΔSL3 mutation is a deletion of nt 300–329, and the ΔSL2,3 mutation is a deletion of nt 284–329. (B) The sequence of a 23-mer derived from the vRNA (TLE²³) is shown next to the anti-codon stem-loop of tRNA^{Lys3} for comparison. This construct contains two additional nonviral 5'-C-G-3' pairs to stabilize the terminal RNA stem. (C) Predicted secondary structure of the MAL construct derived from nt 123–218 of the HIV-1 MAL isolate is shown, with the PBS sequence circled and in bold. The A-rich stem-loop examined in Puglisi and Puglisi (1998) includes nt 156–172.

of the HIV-1 vRNA containing the putative TLE and the PBS (Fig. 1A, nt 123–223). The PBS/TLE RNA bound to hLysRS but not to human prolyl-tRNA synthetase (hProRS) (Fig. 3A). As mammalian LysRS contains a 65-aa N-terminal extension that confers nonspecific RNA-binding (Francin and Mirande 2006), we also tested binding to hLysRSΔN65 and found that it also binds the PBS/TLE (Fig. 3B). Since the truncated protein has been shown to be more sensitive to specific RNA binding interactions (Francin and Mirande 2006), all *in vitro* studies described below were performed with hLysRSΔN65. Additionally, a large fraction of hLysRS in virions is truncated (Cen et al. 2001).

To establish whether hLysRSΔN65 could also bind to the isolated TLE stem-loop, binding to a 23-nt TLE RNA (TLE²³) (Fig. 1B) was tested using fluorescence anisotropy (FA). TLE²³ is derived from the HIV-1 genome (nt 146–164) with two additional C-G closing base pairs to stabilize the stem-loop. Initial studies performed at 15 mM NaCl, 37.5 mM KCl, and 4 mM MgCl₂ were complicated by the de-

pendence of the binding affinity (K_d) on fluorescent RNA concentration (Supplemental Fig. S2A), suggesting that the measured binding affinities (Supplemental Table S1) were underestimated under these conditions. Therefore, FA binding experiments were performed under more stringent conditions (i.e., 15 mM NaCl, 35 mM KCl, 10 mM $MgCl_2$) so that the binding affinities are weak enough to measure accurately without the dependence of K_d on the fluorescent RNA concentration (Supplemental Fig. S2B). Under these conditions, hLysRS Δ N65 bound the TLE²³ (Fig. 3C) with an affinity (K_d = 436 nM), similar to that of in vitro transcribed tRNA^{Lys3} (K_d = 407 nM) or a minihelix derived from the anti-codon stem-loop of tRNA^{Lys3} (anti-codon^{Lys3}, K_d = 268 nM) (Table 1). Human TrpRS and ProRS did not show any significant binding to the TLE²³ even under the less stringent low Mg^{2+} conditions (Supplemental Fig. S3). Mutation of the U-rich TLE loop sequence to AAAA (TLE²³-4A) or CCCC (TLE²³-4C) resulted in a large reduction in binding affinity to hLysRS Δ N65 (K_d > 3 μ M) (Fig. 3C; Table 1), suggesting that binding is mediated through the TLE²³ U-loop residues. Under conditions of lower ionic strength (Supplemental Table S1), hLysRS Δ N65 bound TLE²³-4A and TLE²³-4C ~30- and ~100-fold more than TLE²³, respectively.

Binding of hLysRSΔN65 to longer RNAs was also tested to assess the role of sequences surrounding the TLE stem-loop to LysRS interaction. As shown in Figure 3C, a 330-nt RNA consisting of most of the 5' UTR of the HIV-1 vRNA (Fig. 1A) binds to hLysRSΔN65 with ~6.5-fold greater affinity than the TLE²³ and tRNA^{Lys3} ($K_d = 65.2$ nM) (Table 1). By comparison, mutation of the U-rich motif in the 5' UTR by changing all four Us to Cs (5' UTR-4C) reduced binding

FIGURE 2. The anti-codon loop of human tRNA^{Lys3} is shown aligned with the loop sequence of the TLE (nt 151–157). The % conservation (all) and % conservation of clade B viruses were determined from alignment of ~2170 and 736 HIV-1 sequences, respectively, from the HIV sequence database (<http://www.hiv.lanl.gov/>).

FIGURE 3. Binding studies investigating the specificity of hLysRS/TLE interaction. (A) Electrophoretic mobility shift assays performed with 25 nM 105-nt 32 P-labeled HXB2 PBS/TLE RNA and 0, 0.50, 1.0, 2.0, or 3.0 μ M hLysRS (lanes 1–5) or hProRS (lanes 6–10). (B) Electrophoretic mobility shift assays were performed with 30 nM PBS/TLE and 0, 0.12, 0.18, 0.26, 0.40, 0.59, 0.89, 1.3, 2.0, or 3.0 μ M hLysRSΔN65 (lanes 1–10). (C) FA binding assay wherein varying amounts of hLysRSΔN65 were incubated with 20–50 nM fluorescently labeled TLE²³, TLE²³-4C, 330-nt 5' UTR, or tRNA^{Lys3}. The averages of three experiments with standard deviations are shown.

by approximately threefold ($K_d = 172$ nM) (Table 1), suggesting that binding to the 5' UTR is not mediated only by the anti-codon-like U-rich sequence. The 5' UTR construct consists of TAR, polyA, PBS, SL1, SL2, and SL3 stem-loops (Fig. 1A). To determine the contribution of other 5' UTR elements to high-affinity hLysRSΔN65 binding, 5' UTR

deletion variants Δ TARpolyA, Δ TARpolyA Δ SL3, and Δ TARpolyA Δ SL2 + 3 were constructed. Δ TARpolyA bound hLysRSΔN65 with an affinity only slightly lower ($K_d = 104$ nM) than the 5' UTR (Table 1), suggesting that the presence of the TAR and polyA stem-loops does not greatly enhance binding to hLysRSΔN65. The additional deletion of SL3 also showed little effect (Δ TARpolyA Δ SL3, $K_d = 85.4$ nM). In contrast, deletion of both SL2 and SL3 reduced binding approximately fourfold ($K_d = 281$ nM). Binding to PBS/TLE—which lacks the TAR and polyA stem-loops in addition to SL1, SL2, and SL3—is characterized by an even weaker affinity ($K_d = 383$ nM). However, the Δ TARpolyA Δ SL2,3 variant containing the U153-156C quadruple point mutation bound to hLysRSΔN65 with an affinity ($K_d = 231$ nM) similar to that of Δ TARpolyA Δ SL2,3 (281 nM) and 5' UTR-4C (172 nM). The nonadditivity of these multiple changes on hLysRSΔN65 binding suggests that the interaction between hLysRSΔN65 and the TLE motif is context-dependent and that there may be direct or indirect coupling between these sites. Taken together, these data suggest that the TLE loop is part of a larger structure representing a hLysRS binding domain (LysRS-BD) in the viral RNA. Both SL1 and SL2 (Fig. 1A) in the viral LysRS-BD are required for the highest affinity binding, and the U-rich TLE motif generally contributes less to hLysRS binding to larger 5' UTR-derived RNAs than to shorter RNAs such as TLE²³.

The secondary structure of the NL4-3 vRNA differs from that of the MAL RNA (Goldschmidt et al. 2004). The latter contains sequences in its 5' UTR most similar to HIV-1 clade A viruses (Gao et al. 1998). The region proximal to the PBS in the MAL isolate folds into an A-rich stem-loop (nt 160–170)

TABLE 1. Apparent equilibrium dissociation constants (K_d) for hLysRSΔN65 binding to tRNA^{Lys3} and HIV-1 derived RNAs determined by FA measurements

RNA	K_d (nM)
5' UTR	65.2 $\pm$ 3.1
5' UTR-4C ^a	172 $\pm$ 16
TLE ²³	436 $\pm$ 26
TLE ²³ -4A	>3000 ^b
TLE ²³ -4C ^a	>3000 ^b
Δ TARpolyA	104 $\pm$ 7
Δ TARpolyA Δ SL3	85.4 $\pm$ 5.4
Δ TARpolyA Δ SL2+3	281 $\pm$ 25
Δ TARpolyA Δ SL2+3-4C ^a	231 $\pm$ 17
PBS/TLE	383 $\pm$ 18
Anti-codon ^{Lys3}	268 $\pm$ 14
tRNA ^{Lys3}	407 $\pm$ 33
MAL123–218	313 $\pm$ 47

All measurements were performed in 15 mM NaCl, 35 mM KCl, 20 mM Tris-HCl, pH 7.4, and 10 mM MgCl₂, using 20–50 nM fluorescently labeled RNA. Results are the average of at least three trials with the standard deviations indicated.

^aThe 4C mutation is the quadruple point mutant U153–156C.

^bNo binding was detected up to concentrations of 3000 nM hLysRSΔN65.

(Fig. 1C) which adopts a tRNA-like U-turn motif (Puglisi and Puglisi 1998). To test binding of this region of the MAL isolate to hLysRSΔN65, we prepared an RNA derived from nt 123–218 of the MAL genome (Fig. 1C). MAL123–218 also binds to hLysRSΔN65 with a K_d of 313 nM, which is similar to that observed for the corresponding region of the NL4-3 genome (PBS/TLE, K_d = 383 nM). This finding shows that hLysRSΔN65 binds to tRNA anti-codon-like motifs in both HIV-1 isolate 5' UTRs despite their differences in sequence and secondary structure and suggests that direct binding to these RNAs may depend more on their three-dimensional structures.

HIV-1 genome-derived RNAs compete for hLysRS/tRNA^{Lys3} binding

In the cell, hLysRS interaction with the HIV-1 genome would occur in the presence of tRNA^{Lys3}. Thus, competition binding studies were carried out to determine the extent to which the viral TLE-containing sequences can displace bound tRNA^{Lys3}-derived sequences from hLysRS. When hLysRSΔN65 is prebound to anti-codon^{Lys3} (Fig. 1B, right) prior to TLE²³ addition, the wild-type (WT) TLE²³ (IC_{50} = 980 nM) (Table 2) can effectively compete for binding to anti-codon^{Lys3}, whereas TLE²³-4A cannot (Fig. 4). The tRNA^{Lys3} transcript competes better than the TLE²³ (IC_{50} = 257 nM). Interestingly, the 330-nt 5' UTR RNA competes even more effectively (IC_{50} = 90 nM) (Table 2) than tRNA^{Lys3}, likely due to additional favorable contacts between LysRS-BD and hLysRSΔN65. Competition for tRNA^{Lys3} binding was also tested (Supplemental Fig. S4; Table 3), and a similar result was obtained. When hLysRSΔN65 was prebound to tRNA^{Lys3} and competed with an ~180-nt RNA derived from the Rous sarcoma virus genome (RSV RNA), competition was not observed, but a 105-nt PBS/TLE RNA (nt 127–221) containing the TLE competed modestly for tRNA^{Lys3}, with an IC_{50} of 808 nM. As for the anti-codon^{Lys3} competition assay, the 5' UTR and tRNA^{Lys3} competed simi-

FIGURE 4. FA competition binding experiments. hLysRSΔN65 (200 nM) was prebound to 40 nM fluorescently labeled anti-codon^{Lys3}, followed by titration with the following unlabeled competitor RNAs: 330-nt 5' UTR, in vitro transcribed human tRNA^{Lys3}, TLE²³, and TLE²³-4A.

larly for the tRNA^{Lys3}/hLysRSΔN65 complex (Supplemental Fig. S4), with IC_{50} values of ~200 nM each (Table 3).

The importance of each U for hLysRSΔN65 binding was tested to determine if binding specificity to the TLE resembled the previously established binding specificity for tRNA^{Lys3}. In these assays, hLysRSΔN65 was prebound to tRNA^{Lys3} and titrated with competitor RNAs. The results obtained paralleled the effects of the corresponding point mutations on aminoacylation of tRNA^{Lys3} by hLysRS (Stello et al. 1999). The binding affinity decreased in the order U153C > WT ~ U156C > U155C > U154C > U153-156C (Table 3). U153 corresponds to the wobble base, which is C34 in tRNA^{Lys1,2}. Since hLysRS also aminoacylates this tRNA isoacceptor, mutation to C is not expected to negatively affect hLysRSΔN65 binding. In fact, increased binding of the genomic RNA to hLysRSΔN65 is observed, as indicated by the approximately fourfold lower IC_{50} value obtained with this variant (55.0 nM) (Table 3). Increased IC_{50} values (lower affinity) are observed for the U154C (515 nM) and U155C (372 nM) variants, which correspond to critical tRNA^{Lys3} recognition elements U35 and U36, respectively. The U156C mutation did not alter binding relative to the WT sequence (IC_{50} = 262 nM). Finally, mutation of all four U residues in the U-rich TLE sequence (nt 153–156) to CCCC increased the IC_{50} from 198 nM for WT to 1100 nM, suggesting that the U-rich motif enhances the competition of the 5' UTR for tRNA^{Lys3}/hLysRSΔN65 interaction. Compared to tRNA^{Lys3} aminoacylation data—153-fold and 11-fold decreases in k_{cat}/K_M for tRNA^{Lys3} U35C and U36C variants, respectively (Stello et al. 1999)—the U154C and U155C 5' UTR are only modestly—approximately twofold—defective in competition binding. However, the reductions in k_{cat}/K_M for aminoacylation for these mutations were primarily due to decreased k_{cat} (Stello et al. 1999). In fact, the K_M values for tRNA^{Lys3} WT, U35C, and U36C were 3.4, 7.8, and 3.7 μM, respectively, which are in good agreement with the

TABLE 2. Relative binding affinities of hLysRSΔN65 to HIV-1 genome-derived RNAs based on anti-codon^{Lys3} competition binding assays

RNA	IC_{50} (nM)
TLE ²³	980 ± 35
TLE ²³ -4A	N.D. ^a
5' UTR	90 ± 8.1
tRNA ^{Lys3}	257 ± 14

In these assays, ~40 nM anti-codon^{Lys3} was preincubated with 200 nM hLysRSΔN65 and titrated with competitor RNAs. Reported values are the weighted averages with weighted standard errors shown, which were calculated as described (Taylor 1997) using the experimental values and errors of the IC_{50} for at least three trials. Data are shown in Figure 4.

^aNo competition was observed, so IC_{50} could not be determined (N.D.).

TABLE 3. Relative binding affinities of hLysRSΔN65 to HIV-1 genome-derived RNAs based on tRNA^{Lys3} competition binding assays

RNA	IC ₅₀ (nM)
5' UTR	198 ± 5.6
tRNA ^{Lys3}	217 ± 10
RSV RNA	N.D. ^a
PBS/TLE	808 ± 45
5' UTR-153C	55.0 ± 4.0
5' UTR-154C	515 ± 23
5' UTR-155C	372 ± 14
5' UTR-156C	262 ± 10
5' UTR-4C	1100 ± 120

In these assays, ~40 nM fluorescently labeled tRNA^{Lys3} was pre-bound to 200 nM hLysRSΔN65 and then titrated with competitor RNA. Curves were fit to a 1:1 binding model, and IC₅₀ values were calculated from these curves as described in Materials and Methods. Reported values are the weighted averages with weighted standard errors shown, which were calculated as described (Taylor 1997) using the experimental values and errors of the IC₅₀ for at least three trials. The 5' UTR-4C RNA contains four (U153,154,155,156C) point mutations in the TLE.

^aNo competition was observed, so IC₅₀ could not be determined (N.D.).

tRNA^{Lys3} competition binding data (Table 3; Stello et al. 1999).

Wild-type TLE is required for efficient tRNA^{Lys3} primer annealing

To address the function of the TLE/hLysRS interaction in HIV-1 replication, 293T cells were transfected with either WT BH10 virus or virus containing a CCC mutation in the U154–156 positions of the TLE. Viral production was similar for both WT and mutant virus (CAp24/ml culture medium), and precursor protein processing and amounts of reverse transcriptase (RTp66/p51) and hLysRS in cells were also unaffected (Supplemental Fig. S5). These findings indicate that the CCC mutation does not affect protein production or packaging of hLysRS into virions.

Recent data suggest that tRNA^{Lys3} annealing may be a two-step process, with the initial annealing step promoted by Gag prior to protein processing, followed by final primer/template remodeling by mature nucleocapsid protein (Guo et al. 2009). In protease-negative virions, only Gag-facilitated tRNA^{Lys3} annealing occurs, as no mature nucleocapsid protein is present. Therefore, vRNA was isolated from either WT or protease-negative (Pr[−]) viruses, either lacking or containing the CCC mutation. Hybridization with probes specific for either vRNA or tRNA^{Lys3} indicated that the tRNA^{Lys3}/genomic RNA ratios were similar in all four types of viruses, showing that tRNA^{Lys3} packaging was unaffected, a key control (Fig. 5A,B, “tRNA^{Lys3}/Genome RNA”). The effect of the mutations on reverse transcription initiation from the tRNA^{Lys3} primer was assayed using a previously published strategy (Guo et al. 2009). In this assay, total vRNA is used as the source of primer

tRNA annealed to genomic RNA. An in vitro reverse transcription reaction is performed in the presence of ddATP, resulting in a 6-nt extension product. Images of these 6-nt extension products are shown in Figure 5A and B with values of the quantified bands indicated (“Relative tRNA^{Lys3} initiation”). Quantification of these results shows that the CCC mutation reduces initiation by 68% and 92% in WT (Fig. 5A) and Pr[−] viruses (Fig. 5B), respectively. This is consistent with a reduction in tRNA^{Lys3} annealing resulting from the CCC mutation. Moreover, as the defect in annealing is more severe in Pr[−] viruses, the results reinforce nucleocapsid protein's role in repositioning or remodeling the primer/template complex prior to initiation by reverse transcriptase.

To assess the effect of the TLE mutation on viral infection, single-round infectivity of WT and CCC mutant viruses was measured using a luciferase reporter system, in which TMZ-bl cells are used that contain a luciferase gene under the control of an HIV-1 promoter (Wei et al. 2002). The CCC mutation causes a 40% reduction in infectivity (Fig. 5C), which is less than the expected reduction based on the primer extension assay. This may, in part, be due to the lack of a strict correlation between the number of cDNA transcripts produced and the number integrated into the host genome. The fact that the TLE is not absolutely essential for tRNA^{Lys3} placement and viral infectivity is, however, consistent with the significant contributions of sequence elements outside the U-rich loop to hLysRS binding.

Thus, the reduced ability of the CCC mutation to bind LysRS (Table 3) does not result in less viral production (Supplemental Fig. S5) but does result in reduced infectivity. This is not surprising since virus production from cells transfected with viral DNA does not depend upon tRNA^{Lys3}-primed reverse transcription to produce new proviral DNA

FIGURE 5. Effect of TLE loop mutations on the incorporation of tRNA^{Lys3} into HIV-1, the initiation of reverse transcription, and viral infectivity. WT and protease-negative (Pr[−]) virus were produced from transfected 293T cells. (A) Results of WT virus with or without the U154–156C mutation. The tRNA^{Lys3}:vRNA ratio (top) was determined by hybridizing RNA with specific DNA probes. In the initiation assay (bottom), total vRNA was used as the source of primer/template. A denaturing polyacrylamide gel shows the results of 6-nt primer extension assays performed with WT virus (BH10[UUU]) or virus containing a triple mutation in the TLE (BH10[CCC]). (B) The results of tRNA packaging and primer extension assays similar to those described in A, performed with Pr[−] virus. (C) Single-round viral infectivity of TZM-bl cells transfected with WT or CCC mutant virus, normalized to BH10. TZM-bl cells contain an integrated copy of the luciferase gene behind the HIV-1 promoter, and infectivity was measured by using the luciferase activity in the lysates of cells 48 h post-transfection.

whose integration into the host cell's genome will lead to the production of viral proteins. On the other hand, the viruses produced from such transfected cells might be expected to be less infectious (Fig. 5C), i.e., produce less viral DNA and proteins upon a new round of infection, if the CCC mutant results in less tRNA^{Lys3} annealed to the viral RNA.

DISCUSSION

The data presented here show that the HIV-1 vRNA contains a tRNA anti-codon-like element proximal to the PBS that is part of a larger binding domain for hLysRS. The TLE confers specific binding to hLysRS (Fig. 3A), but additional sequence elements, including SL1 and SL2, are involved in high-affinity binding (Table 1). In the isolated TLE stem-loop, the U-rich motif is essential for hLysRSΔN65 binding; however, in larger RNAs containing the TLE stem-loop, the contribution of the U-rich motif is less important. WT TLE-containing sequences effectively compete for hLysRSΔN65/tRNA^{Lys3} interaction in vitro, and mutation of the U-rich loop, which mimics the tRNA^{Lys3} anti-codon loop, reduces tRNA^{Lys3} annealing in virions. The presence of a LysRS-BD in the 5' UTR may also promote binding of Gag/hLysRS/tRNA^{Lys3} complexes over those that do not contain hLysRS. Thus, these findings are consistent with a model in which HIV-1 uses molecular mimicry of tRNA^{Lys} to increase the efficiency of tRNA primer annealing by providing a site of preferential hLysRS binding (Fig. 6). The simplified model in Figure 6 suggests that binding of hLysRS to the TLE may promote tRNA^{Lys3} annealing through release of tRNA^{Lys3} from hLysRS; however, the annealing of tRNA^{Lys3} to viral RNA takes place within a Gag/GagPol nucleoprotein complex that also promotes this process (Saadatmand and Kleiman 2012). Within this complex, hLysRS has been reported to have multiple interactions with

sequences within both Gag (Javanbakht et al. 2003; Kovaleski et al. 2007) and Pol (Saadatmand et al. 2008), and we report here an additional interaction with the TLE in the viral RNA. While this interaction may promote tRNA^{Lys3} annealing to the nearby PBS sequence by facilitating the release of tRNA^{Lys3} from LysRS, it might also help promote the localization of the hLysRS/tRNA^{Lys3}-containing nucleoprotein complex to the site of annealing within the large vRNA genome. Thus, mutation of the U-rich sequence within the TLE reduces annealing by either reducing recruitment of the hLysRS/tRNA^{Lys3} complex or by weakening the competition of the TLE for hLysRS/tRNA^{Lys3} and thereby preventing the subsequent release of tRNA^{Lys3} for annealing and priming.

The clade B virus TLE studied here mimics tRNA^{Lys3} more closely than the putative TLE sequence from other virus clades (Supplemental Fig. S1). Previously published chemical and enzymatic probing of the initiation complex of the MAL isolate has shown that an alternate secondary structure is preferred in which a U-rich loop is not exposed (Fig. 1C; Isel et al. 1995; Goldschmidt et al. 2004). Instead, in these isolates an A-rich stem-loop is present with a tRNA anti-codon-like U-turn structure (Puglisi and Puglisi 1998; Goldschmidt et al. 2004), and this loop is hypothesized to interact with tRNA^{Lys3} via its complementarity to the U-rich anti-codon sequence (Isel et al. 1995; Puglisi and Puglisi 1998). Extensive tRNA/genome interactions outside the PBS have been proposed based on structure probing studies of the MAL isolate (Goldschmidt et al. 2004). Despite the differences in predicted secondary structure between MAL and NL4-3 5' UTRs, both contain an anti-codon-like stem-loop upstream of the PBS (Goldschmidt et al. 2004), and both bind to hLysRSΔN65. Additional studies are needed to establish whether the tRNA anti-codon-like stem-loops in different virus clades share a common function in promoting efficient tRNA primer annealing. Interestingly, in vitro selection for RNA aptamers that bind to hLysRSΔN65 has revealed that high-affinity hLysRS-binding RNAs fall primarily into two classes with consensus motifs containing either a U-rich or A-rich loop (A Curtright, W Wang, and K Musier-Forsyth, in prep.).

HIV-1 may take advantage of tRNA mimicry for an additional purpose. In Dicistroviridae viruses (Costantino et al. 2008; Zhu et al. 2011), tRNA mimicry is critical for internal ribosome entry site (IRES) function. Although many retroviruses contain an IRES (Balvay et al. 2009), the presence of an IRES in HIV-1 is somewhat controversial (Miele et al. 1996; Brasey et al. 2003) as the IRES appears to be active only under certain physiological conditions, such as G2/M arrest (Brasey et al. 2003) or stress (Gendron et al. 2011), and there is also evidence that ribosomal scanning occurs in part of the 5' UTR (Berkhout et al. 2011). In recent studies (Brasey et al. 2003; Gendron et al. 2011), IRES activity mapped to a region in the 5' UTR overlapping with the TLE described herein. Taken together, these findings suggest that the TLE might be part of an IRES that aids in ribosome recruitment via tRNA mimicry. Recently, glycyl-tRNA synthetase (GlyRS) was shown to bind

FIGURE 6. Hypothetical model for TLE-assisted tRNA^{Lys3} primer placement. The tRNA^{Lys3} primer shares 18 nt of complementarity (red) to the HIV-1 vRNA and must be annealed for reverse transcription to begin from the primer's CCA-3' OH end. Human LysRS and tRNA^{Lys3} are packaged as a complex along with genomic RNA, which has a TLE (yellow) upstream of the primer binding site (PBS) (blue). Although the full extent to which the TLE-containing viral RNA mimics the structure of a tRNA is unknown, the TLE is part of a LysRS binding domain (LysRS-BD) that effectively competes for binding to hLysRS (green, two domains representing catalytic and anti-codon-binding domains). This competition may facilitate release of bound tRNA^{Lys3} from the synthetase, which can then be annealed to the vRNA. Arrows indicate intermediate steps in the annealing pathway, which requires viral proteins that facilitate tRNA^{Lys3} annealing such as Gag and GagPol (omitted for clarity).

to the poliovirus IRES to activate translation initiation (Andreev et al. 2012). Thus, a common strategy employed by viruses may be to recruit aminoacyl-tRNA synthetases, which are well-established to have moonlighting roles outside of protein translation (Nechushtan et al. 2009; Kim et al. 2011).

NMR studies using the hLysRS anti-codon binding domain support a direct interaction between the HIV-1 TLE loop and LysRS (S Liu, CP Jones, K Musier-Forsyth, and P Tsang, in prep.). Additional biophysical studies are needed to determine the extent to which the LysRS-BD in the 5' UTR imitates other structural features of tRNA^{Lys3}. Binding studies comparing the 5' UTR 330-mer to deletion constructs indicated that the TARpolyA and SL3 domains are dispensable but that the SL1/SL2 region of the 5' UTR contributes to high-affinity LysRS binding, possibly by stabilizing a tRNA-like structure or by directly interacting with LysRS. Mutating the anti-codon-like sequence of the TLE in the context of the 5' UTR was not sufficient to abolish LysRS interaction in vitro or viral infectivity in cell-based assays, consistent with the involvement of other vRNA sequences. Testing a true "LysRS-BD-minus" mutant virus in cell-based assays may be difficult due to the critical role that these sequence elements play in other steps of the virus life cycle—SL1 contains the dimerization initiation site, SL2 contains the splice donor site, and SL2 and SL3 are part of the Psi packaging signal (Coffin et al. 1997; De Guzman et al. 1998; Amarasinghe et al. 2000).

Previous studies identified a nonanucleotide sequence located in the U3 region at the 3' end of the HIV-1 vRNA complementary to nt 38–46 of tRNA^{Lys3} (Brule et al. 2000; Song et al. 2009). Recently, Bambara and coworkers discovered a much longer sequence element that resembles the tRNA^{Lys3} gene embedded in the 3' end of the HIV-1 vRNA and closely related lentiviral genomes (Piekna-Przybylska et al. 2010). This sequence includes the previously identified nonanucleotide sequence, has extensive complementarity to tRNA^{Lys3}, and even contains a vestigial intron inserted in approximately the position expected for a tRNA intron. In vitro studies showed that including this extended sequence in the acceptor template further enhances the efficiency of minus-strand transfer beyond that observed with the 9-nt segment (Piekna-Przybylska et al. 2010). Thus, functionally important sequence elements with extensive complementarity to tRNA^{Lys3} are present in the 5' and 3' UTR of HIV-1 genomic RNA (i.e., the 5' PBS region and 3' tRNA^{Lys3}-like gene). The identification of the anti-codon-like TLE reported here provides a third example of a functionally relevant tRNA^{Lys}-derived sequence that is present in the HIV-1 genome.

MATERIALS AND METHODS

Preparation of proteins and nucleic acids

Human LysRS (Shiba et al. 1997), LysRSΔN65 (Shiba et al. 1997), TrpRS (Wakasugi et al. 2002), and ProRS (Heacock et al. 1996)

were prepared as previously described. Each protein contains a His₆ tag and was purified using Ni²⁺-NTA resin (Qiagen), Co²⁺ Talon resin (Clontech), or His-select resin (Sigma). Protein concentrations were determined using the Bradford assay with BSA as a standard (Bio-Rad). Active site titrations were used for assaying TrpRS and ProRS enzyme activities (Fersht et al. 1975). Enzyme activity was additionally tested using aminoacylation assays with in vitro transcribed human tRNA^{Lys3} in the case of hLysRS and hLysRSΔN65 and human tRNA^{Pro} in the case of ProRS (Heacock et al. 1996; Shiba et al. 1997).

Short RNAs (TLE²³, TLE²³-4A, TLE²³-4C, and anti-codon^{Lys3}) were purchased from Dharmacon. All other RNAs—330-nt HIV-1 5' UTR variants, 206-nt ΔTARpolyA, 186-nt ΔTARpolyA ΔSL3, 169-nt ΔTARpolyA ΔSL2+3, 105-nt TARpolyA, 105-nt NL4-3 PBS/TLE, 105-nt HXB2 PBS/TLE, 98-nt Psi RNA, 76-nt human tRNA^{Lys3}, 180-nt RSV RNA, and 98-nt MAL123–218 RNA—were prepared by in vitro transcription using T7 RNA polymerase (Milligan et al. 1987) and purified using denaturing (8 M urea) polyacrylamide gel electrophoresis. Extinction coefficients at 260 nm used for the UTR-derived RNAs are as follows: 5' UTR WT and U-to-C mutants, $304 \times 10^4 \text{ M}^{-1} \text{ cm}^{-1}$; NL4-3 and HXB2 PBS/TLE, $95.5 \times 10^4 \text{ M}^{-1} \text{ cm}^{-1}$; ΔTARpolyA, $190 \times 10^4 \text{ M}^{-1} \text{ cm}^{-1}$; ΔTARpolyA ΔSL3, $162 \times 10^4 \text{ M}^{-1} \text{ cm}^{-1}$; ΔTARpolyA ΔSL2+3, $146 \times 10^4 \text{ M}^{-1} \text{ cm}^{-1}$; ΔTARpolyA ΔSL2+3-4C, $146 \times 10^4 \text{ M}^{-1} \text{ cm}^{-1}$; MAL123–218, $87 \times 10^4 \text{ M}^{-1} \text{ cm}^{-1}$. The 76-nt tRNA^{Lys3} used in this study was prepared as described previously (Shiba et al. 1997). The gene encoding the 330-nt HIV-1 5' UTR RNA was amplified from pMSMΔEnv (McBride and Panganiban 1996) using PCR and cloned into PstI and BamHI restriction sites of pET15b (Novagen) behind a T7 promoter. The resulting plasmid (pHIV330) was digested with FokI to generate the DNA template for in vitro transcription reactions. The sequence of the RNA resulting from in vitro transcription is identical to the first 329 nt of the HIV-1 vRNA with an additional G placed at the 5' end to improve transcription efficiency. From this clone, genes encoding other genomic RNAs were made using standard PCR and Quikchange mutagenesis procedures (Stratagene). The plasmid pMAL123–218 encoding the MAL123–218 RNA was cloned from pJCB (Paillart et al. 1994), a gift of Dr. Roland Marquet (Université de Strasbourg). This RNA is derived from MAL nt 123–218 with two additional G residues placed at the 5' end for efficient in vitro transcription. Prior to use, the 96- to 330-nt RNAs were folded by heating to 85°C for 2.5 min, 50°C for 8 min, adding MgCl₂ to 10 mM, heating at 37°C for 10 min, and cooling on ice for at least 30 min. Shorter RNAs (tRNA^{Lys3}, anti-codon^{Lys3}, and TLE²³) were folded by heating for 2 min at 80°C, 2 min at 60°C, adding MgCl₂ to 10 mM, and cooling on ice for at least 30 min.

Radiolabeled RNAs used in EMSAs were prepared by treating ~150 pmol RNA with calf intestine phosphatase and 5' end-labeling with γ-³²P-ATP using T4 polynucleotide kinase (New England Biolabs). ³²P-labeled RNAs were purified using G-25 spin columns (Roche), aliquoted, and stored at –20°C in diethylpyrocarbonate (DEPC)-treated H₂O.

Fluorescently labeled RNAs were prepared using previously described methods (Pagano et al. 2007) with some modifications. In 100 mM sodium acetate, pH 5.1, 5 nmol RNA was treated with 10-fold excess sodium periodate in a 50-μL reaction volume for 1.5 h at room temperature in the dark. The reaction was quenched with 5 μL glycerol and ethanol precipitated. The pellet from the ethanol precipitation was resuspended in 50 μL 100 mM sodium

acetate, pH 5.1, with 1 mM fluorescein-5-semithiocarbamide and incubated at 4°C in the dark for 18–24 h. The mixture was then eluted through a G-25 spin column (Roche) to remove free dye and checked for purity using 1% agarose or denaturing polyacrylamide gel electrophoresis (8% or 12% gels, depending on RNA length). Labeling efficiency was determined by measuring the UV absorbances at 260 nm and 495 nm at pH 8 and using the following extinction coefficients (and those above): fluorescein, $8.5 \times 10^4 \text{ M}^{-1} \text{ cm}^{-1}$ (pH 8); anti-codon^{Lys3}, $32.8 \times 10^4 \text{ M}^{-1} \text{ cm}^{-1}$; tRNA^{Lys3}, $60.4 \times 10^4 \text{ M}^{-1} \text{ cm}^{-1}$; TLE²³, $22.1 \times 10^4 \text{ M}^{-1} \text{ cm}^{-1}$; TLE²³-4A, $23.0 \times 10^4 \text{ M}^{-1} \text{ cm}^{-1}$; TLE²³-4C, $21.0 \times 10^4 \text{ M}^{-1} \text{ cm}^{-1}$. Labeling efficiencies were typically between 60% and 80%. RNAs were aliquoted after labeling and stored in DEPC-treated H₂O in amber tubes at –20°C.

Electrophoretic mobility shift assays

Prior to use, RNAs were refolded as described above. ³²P-labeled RNA substrate (25 nM) was mixed with varying amounts of protein (final concentrations in Fig. 3 legend) in 10 mM Tris-HCl, pH 7.4, 75 mM KCl, 10 mM MgCl₂, and 5% glycerol. Binding reactions (10 µL) were incubated for 30 min at room temperature and mixed with 4 µL loading dye (50% glycerol, xylene cyanol, bromophenol blue) prior to electrophoresis on a 6% native polyacrylamide gel at 4°C. Gels were dried and exposed overnight, and band intensities were visualized and quantified using a Typhoon Trio phosphorimager (GE Healthcare).

Fluorescence anisotropy equilibrium binding measurements

Reaction mixtures contained 20 mM Tris-HCl, pH 7.4, 35 mM KCl, 10 mM MgCl₂, 15 mM NaCl, 20–50 nM labeled RNA, and various protein concentrations. Reactions were incubated for 30 min in amber tubes at room temperature. Aliquots (20 µL) were read in 384-well plates using a SpectraMax M5 plate reader system (Molecular Devices) by exciting at 485 nm and measuring emission at 530 nm. FA binding curves were fit to a 1:1 binding model (Stewart-Maynard et al. 2008).

For competition assays, either 40 nM fluorescently labeled tRNA^{Lys3} or anti-codon^{Lys3} was incubated with 200 nM hLysRS ΔN65 in 10 mM Tris-HCl, pH 7.4, 37.5 mM KCl, 5 mM MgCl₂, and 15 mM NaCl. Under these conditions, the difference between the anisotropy of the complex and the anisotropy of the free RNA is large enough that competition binding curves show significant and reproducible changes upon titration with competitor. Conditions in competition assays were identical to binding conditions. After incubation of hLysRSΔN65 with the fluorescently labeled RNA for 30 min at room temperature, competitor RNA was added, and the mixture was incubated 30 min at room temperature. To establish points for normalization, the anisotropy of the free RNA in the absence of hLysRSΔN65 (r_{free}) and the anisotropy of the complex without competitor (r_{bound}) were also measured.

Competition binding curves were normalized by using the following equation: $(r - r_{\text{free}})/(r_{\text{bound}} - r_{\text{free}})$. This normalization sets r_{bound} to “100% RNA bound” and r_{free} to “0% RNA bound.” For determination of IC₅₀, competition binding curves were fit to the same 1:1 binding model used above, as previously described (Stewart-Maynard et al. 2008).

Cells, transfections, and virus purification

A description of the plasmids used is given in the Supplemental Material, Methods. HEK-293T cells were grown in complete Dulbecco’s modified Eagle’s medium plus 10% fetal bovine serum, 100 units of penicillin, and 100 µg of streptomycin/ml. For the production of viruses, HEK-293T cells were transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. Supernatant was collected 48 h post-transfection. Viruses were pelleted from culture medium by centrifugation in a Beckman SW41 rotor at 35,000 rpm for 1 h through a 20% sucrose cushion. The pellet of purified virus was resuspended in 1× TNE (20 mM Tris, pH 7.8, 100 mM NaCl, 1 mM EDTA).

Viral RNA isolation

Total vRNA was extracted from viral pellets using the guanidinium isothiocyanate procedure as previously described (Huang et al. 1994) and was dissolved in RNase free, DEPC-treated dH₂O.

Real-time PCR quantification of viral genomic RNA and tRNA^{Lys3}

RT-PCR was performed upon vRNA and tRNA^{Lys3} using SuperScript One-Step RT/PCR with Platinum Taq (Invitrogen Life Technologies). Primers for quantifying genomic RNA encompassed nt 710–910: forward, 5′-GAGATGGGTGCGAGAGCGTCA GTA-3′; reverse, 5′-GCTCCCTGCTTGCCCATATATATGT-3′. Primers for quantifying tRNA^{Lys3}: forward, 5′-GTCGGTAGAGCA TCAGACTT-3′; reverse, 5′-CGCCCGAACAGGGACTT-3′.

tRNA^{Lys3}-primed initiation of reverse transcription

Total RNA isolated from virus produced in transfected 293T cells was used as the source of primer tRNA annealed in vivo to vRNA in an in vitro reverse transcription reaction, as previously described (Huang et al. 1996). Briefly, total vRNA was incubated at 37°C for 15 min in 20 µL of RT buffer (50 mM Tris-HCl [pH 7.5], 60 mM KCl, 3 mM MgCl₂, and 10 mM dithiothreitol) containing 50 ng purified HIV RT, 10 units of RNasin, and various deoxynucleotide triphosphates (dNTPs). To measure the ability of annealed tRNA^{Lys3} to be extended by six deoxyribonucleotides, the RT reaction mixture contained 200 µM dCTP, 200 µM dTTP, 5 µCi of [α]-³²P dGTP (0.16 µM), and 50 µM ddATP. Reaction products were resolved by polyacrylamide gel electrophoresis using a 6% polyacrylamide gel containing 7 M urea (Huang et al. 1996).

Virus infectivity assay

Single-cycle infectivity levels were determined by challenging 10⁵ TZM-bl indicator cells (Wei et al. 2002) with equal amounts of viruses (corresponding to 20 ng of CAp24) that had been produced from HEK-293T cells transfected with wild-type or mutant HIV-1 DNA. The induced expression of luciferase activity in cell lysates was measured after 48 h. TZM-bl indicator cells were generated from the stably transfected CD4+ Hela cell line, JC53, by introducing separate integrated copies of the luciferase and β-galactosidase genes under control of the HIV-1 promoter. Infection was measured

by the induction of luciferase activity by newly synthesized HIV-1 proteins and was measured using a Lumat LB9507 luminometer (EG&G Berthold).

SUPPLEMENTAL MATERIAL

Supplemental material is available for this article.

ACKNOWLEDGMENTS

We thank Medha Raina for performing initial gel shift experiments and Dr. Roland Marquet (Université de Strasbourg) for the plasmid pJCB. We also thank Tiffany Rye-McCurdy, Joseph Webb, and Maheen Masood for assistance with protein purification and Roopa Comandur for assistance with MAL RNA preparation. This work was supported by NIH grant RO1 AI077387 (to L.K. and K.M.-F.). C.P.J. was supported by NIH Training Grant T32 GM008512 and a Center for RNA Biology Fellowship from Ohio State University.

Received October 2, 2012; accepted November 14, 2012.

REFERENCES

- Amarasinghe GK, De Guzman RN, Turner RB, Summers MF. 2000. NMR structure of stem-loop SL2 of the HIV-1 Ψ RNA packaging signal reveals a novel A-U-A base-triple platform. *J Mol Biol* **299**: 145–156.
- Andreev DE, Hirnet J, Terenin IM, Dmitriev SE, Niepmann M, Shatsky IN. 2012. Glycyl-tRNA synthetase specifically binds to the poliovirus IRES to activate translation initiation. *Nucleic Acids Res* **40**: 5602–5614.
- Arts EJ, Stetor SR, Li X, Rausch JW, Howard KJ, Ehresmann B, North TW, Wohrl BM, Goody RS, Wainberg MA, et al. 1996. Initiation of (–) strand DNA synthesis from tRNA^{Lys} on lentiviral RNAs: Implications of specific HIV-1 RNA-tRNA^{Lys} interactions inhibiting primer utilization by retroviral reverse transcriptases. *Proc Natl Acad Sci* **93**: 10063–10068.
- Balvay L, Soto Rifo R, Ricci EP, Decimo D, Ohlmann T. 2009. Structural and functional diversity of viral IRESes. *Biochim Biophys Acta* **1789**: 542–557.
- Beerens N, Groot F, Berkhout B. 2001. Initiation of HIV-1 reverse transcription is regulated by a primer activation signal. *J Biol Chem* **276**: 31247–31256.
- Berkhout B, Arts K, Abbink TE. 2011. Ribosomal scanning on the 5′-untranslated region of the human immunodeficiency virus RNA genome. *Nucleic Acids Res* **39**: 5232–5244.
- Bolinger C, Boris-Lawrie K. 2009. Mechanisms employed by retroviruses to exploit host factors for translational control of a complicated proteome. *Retrovirology* **6**: 8.
- Brasey A, Lopez-Lastra M, Ohlmann T, Beerens N, Berkhout B, Darlix JL, Sonenberg N. 2003. The leader of human immunodeficiency virus type 1 genomic RNA harbors an internal ribosome entry segment that is active during the G2/M phase of the cell cycle. *J Virol* **77**: 3939–3949.
- Brule F, Bec G, Keith G, Le Grice SF, Roques BP, Ehresmann B, Ehresmann C, Marquet R. 2000. In vitro evidence for the interaction of tRNA^{Lys} with U3 during the first strand transfer of HIV-1 reverse transcription. *Nucleic Acids Res* **28**: 634–640.
- Cen S, Khorchid A, Javanbakht H, Gabor J, Stello T, Shiba K, Musier-Forsyth K, Kleiman L. 2001. Incorporation of lysyl-tRNA synthetase into human immunodeficiency virus type 1. *J Virol* **75**: 5043–5048.
- Cen S, Javanbakht H, Kim S, Shiba K, Craven R, Rein A, Ewalt K, Schimmel P, Musier-Forsyth K, Kleiman L. 2002. Retrovirus-specific packaging of aminoacyl-tRNA synthetases with cognate primer tRNAs. *J Virol* **76**: 13111–13115.
- Coffin JM, Hughes SH, Varmus H. 1997. *Retroviruses*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
- Costantino DA, Pfingsten JS, Rambo RP, Kieft JS. 2008. tRNA-mRNA mimicry drives translation initiation from a viral IRES. *Nat Struct Mol Biol* **15**: 57–64.
- Damgaard CK, Dyhr-Mikkelsen H, Kjems J. 1998. Mapping the RNA binding sites for human immunodeficiency virus type-1 gag and NC proteins within the complete HIV-1 and -2 untranslated leader regions. *Nucleic Acids Res* **26**: 3667–3676.
- De Guzman RN, Wu ZR, Stalling CC, Pappalardo L, Borer PN, Summers MF. 1998. Structure of the HIV-1 nucleocapsid protein bound to the SL3 Ψ -RNA recognition element. *Science* **279**: 384–388.
- Dreher TW. 2009. Role of tRNA-like structures in controlling plant virus replication. *Virus Res* **139**: 217–229.
- Feng YX, Campbell S, Harvin D, Ehresmann B, Ehresmann C, Rein A. 1999. The human immunodeficiency virus type 1 Gag polyprotein has nucleic acid chaperone activity: Possible role in dimerization of genomic RNA and placement of tRNA on the primer binding site. *J Virol* **73**: 4251–4256.
- Fersht AR, Ashford JS, Bruton CJ, Jakes R, Koch GL, Hartley BS. 1975. Active site titration and aminoacyl adenylate binding stoichiometry of aminoacyl-tRNA synthetases. *Biochemistry* **14**: 1–4.
- Francin M, Mirande M. 2006. Identity elements for specific aminoacylation of a tRNA by mammalian lysyl-tRNA synthetase bearing a nonspecific tRNA-interacting factor. *Biochemistry* **45**: 10153–10160.
- Francin M, Kaminska M, Kerjan P, Mirande M. 2002. The N-terminal domain of mammalian lysyl-tRNA synthetase is a functional tRNA-binding domain. *J Biol Chem* **277**: 1762–1769.
- Gabor J, Cen S, Javanbakht H, Niu M, Kleiman L. 2002. Effect of altering the tRNA^{Lys3} concentration in human immunodeficiency virus type 1 upon its annealing to viral RNA, GagPol incorporation, and viral infectivity. *J Virol* **76**: 9096–9102.
- Gao F, Robertson DL, Carruthers CD, Li Y, Bailes E, Kostrikis LG, Salminen MO, Bibollet-Ruche F, Peeters M, Ho DD, et al. 1998. An isolate of human immunodeficiency virus type 1 originally classified as subtype I represents a complex mosaic comprising three different group M subtypes (A, G, and I). *J Virol* **72**: 10234–10241.
- Gao F, Kasprzak W, Stupina VA, Shapiro BA, Simon AE. 2012. A ribosome-binding, 3′ translational enhancer has a T-shaped structure and engages in a long-distance RNA-RNA interaction. *J Virol* **86**: 9828–9842.
- Gendron K, Ferbeyre G, Heveker N, Brakier-Gingras L. 2011. The activity of the HIV-1 IRES is stimulated by oxidative stress and controlled by a negative regulatory element. *Nucleic Acids Res* **39**: 902–912.
- Goldschmidt V, Paillart JC, Rigourd M, Ehresmann B, Aubertin AM, Ehresmann C, Marquet R. 2004. Structural variability of the initiation complex of HIV-1 reverse transcription. *J Biol Chem* **279**: 35923–35931.
- Guo F, Cen S, Niu M, Javanbakht H, Kleiman L. 2003. Specific inhibition of the synthesis of human lysyl-tRNA synthetase results in decreases in tRNA^{Lys} incorporation, tRNA^{Lys} annealing to viral RNA, and viral infectivity in human immunodeficiency virus type 1. *J Virol* **77**: 9817–9822.
- Guo F, Gabor J, Cen S, Hu K, Moulard AJ, Kleiman L. 2005. Inhibition of cellular HIV-1 protease activity by lysyl-tRNA synthetase. *J Biol Chem* **280**: 26018–26023.
- Guo F, Saadatmand J, Niu M, Kleiman L. 2009. Roles of Gag and NCp7 in facilitating tRNA^{Lys3} annealing to viral RNA in human immunodeficiency virus type 1. *J Virol* **83**: 8099–8107.
- Hammond JA, Rambo RP, Filbin ME, Kieft JS. 2009. Comparison and functional implications of the 3D architectures of viral tRNA-like structures. *RNA* **15**: 294–307.
- Heacock D, Forsyth C, Shiba K, Musier-Forsyth K. 1996. Synthesis and aminoacyl-tRNA synthetase inhibitory activity of prolyl adenylate analogs. *Bioorg Chem* **24**: 273–289.
- Huang Y, Mak J, Cao Q, Li Z, Wainberg MA, Kleiman L. 1994. Incorporation of excess wild type and mutant tRNA^{Lys3} into HIV-1. *J Virol* **68**: 7676–7683.

- Huang Y, Shalom A, Li Z, Wang J, Mak J, Wainberg MA, Kleiman L. 1996. Effects of modifying the tRNA^{Lys3} anticodon on the initiation of Human Immunodeficiency Virus Type 1 reverse transcription. *J Virol* **70**: 4700–4706.
- Huang Y, Wang J, Shalom A, Li Z, Khorchid A, Wainberg MA, Kleiman L. 1997. Primer tRNA^{Lys} on the viral genome exists in unextended and two-base extended forms within mature human immunodeficiency virus type 1. *J Virol* **71**: 726–728.
- Isel C, Marquet R, Keith G, Ehresmann C, Ehresmann B. 1993. Modified nucleotides of tRNA^{Lys} modulate primer/template loop-loop interaction in the initiation complex of HIV-1 reverse transcription. *J Biol Chem* **268**: 25269–25272.
- Isel C, Ehresmann C, Keith G, Ehresmann B, Marquet R. 1995. Initiation of reverse transcription of HIV-1: Secondary structure of the HIV-1 RNA/tRNA^{Lys} (template/primer). *J Mol Biol* **247**: 236–250.
- Iwatani Y, Rosen AE, Guo J, Musier-Forsyth K, Levin JG. 2003. Efficient initiation of HIV-1 reverse transcription in vitro. Requirement for RNA sequences downstream of the primer binding site abrogated by nucleocapsid protein-dependent primer-template interactions. *J Biol Chem* **278**: 14185–14195.
- Javanbakht H, Cen S, Musier-Forsyth K, Kleiman L. 2002. Correlation between tRNA^{Lys3} aminoacylation and its incorporation into HIV-1. *J Biol Chem* **277**: 17389–17396.
- Javanbakht H, Halwani R, Cen S, Saadatmand J, Musier-Forsyth K, Gottlinger H, Kleiman L. 2003. The interaction between HIV-1 Gag and human lysyl-tRNA synthetase during viral assembly. *J Biol Chem* **278**: 27644–27651.
- Jiang M, Mak J, Ladha A, Cohen E, Klein M, Rovinski B, Kleiman L. 1993. Identification of tRNAs incorporated into wild-type and mutant human immunodeficiency virus type 1. *J Virol* **67**: 3246–3253.
- Jones CP, Datta SA, Rein A, Rouzina I, Musier-Forsyth K. 2011. Matrix domain modulates HIV-1 Gag's nucleic acid chaperone activity via inositol phosphate binding. *J Virol* **85**: 1594–1603.
- Khorchid A, Javanbakht H, Wise S, Halwani R, Parniak MA, Wainberg MA, Kleiman L. 2000. Sequences within Pr160^{gag-pol} affecting the selective packaging of primer tRNA^{Lys3} into HIV-1. *J Mol Biol* **299**: 17–26.
- Kim S, You S, Hwang D. 2011. Aminoacyl-tRNA synthetases and tumorigenesis: More than housekeeping. *Nat Rev Cancer* **11**: 708–718.
- Kleiman L, Jones CP, Musier-Forsyth K. 2010. Formation of the tRNA^{Lys} packaging complex in HIV-1. *FEBS Lett* **584**: 359–365.
- Kobbi L, Octobre G, Dias J, Comisso M, Mirande M. 2011. Association of mitochondrial lysyl-tRNA synthetase with HIV-1 GagPol involves catalytic domain of the synthetase and transframe and integrase domains of Pol. *J Mol Biol* **410**: 875–886.
- Kovaleski BJ, Kennedy R, Khorchid A, Kleiman L, Matsuo H, Musier-Forsyth K. 2007. Critical role of helix 4 of HIV-1 capsid C-terminal domain in interactions with human lysyl-tRNA synthetase. *J Biol Chem* **282**: 32274–32279.
- Li M, Kao E, Gao X, Sandig H, Limmer K, Pavon-Eternod M, Jones TE, Landry S, Pan T, Weitzman MD, et al. 2012. Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11. *Nature* **491**: 125–128.
- McBride MS, Panganiban AT. 1996. The human immunodeficiency virus type 1 encapsidation site is a multipartite RNA element composed of functional hairpin structures. *J Virol* **70**: 2963–2973.
- Miele G, Moulard A, Harrison GP, Cohen E, Lever AM. 1996. The human immunodeficiency virus type 1 5' packaging signal structure affects translation but does not function as an internal ribosome entry site structure. *J Virol* **70**: 944–951.
- Milligan JF, Groebe DR, Witherell GW, Uhlenbeck OC. 1987. Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates. *Nucleic Acids Res* **15**: 8783–8798.
- Nechushtan H, Kim S, Kay G, Razin E. 2009. Chapter 1: The physiological role of lysyl tRNA synthetase in the immune system. *Adv Immunol* **103**: 1–27.
- Pagano JM, Farley BM, McCoig LM, Ryder SP. 2007. Molecular basis of RNA recognition by the embryonic polarity determinant MEX-5. *J Biol Chem* **282**: 8883–8894.
- Paillart JC, Marquet R, Skripkin E, Ehresmann B, Ehresmann C. 1994. Mutational analysis of the bipartite dimer linkage structure of human immunodeficiency virus type 1 genomic RNA. *J Biol Chem* **269**: 27486–27493.
- Pavon-Eternod M, Wei M, Pan T, Kleiman L. 2010. Profiling non-lysyl tRNAs in HIV-1. *RNA* **16**: 267–273.
- Piekna-Przybylska D, DiChiacchio L, Mathews DH, Bambara RA. 2010. A sequence similar to tRNA^{Lys} gene is embedded in HIV-1 U3-R and promotes minus-strand transfer. *Nat Struct Mol Biol* **17**: 83–89.
- Puglisi EV, Puglisi JD. 1998. HIV-1 A-rich RNA loop mimics the tRNA anticodon structure. *Nat Struct Biol* **5**: 1033–1036.
- Roldan A, Warren OU, Russell RS, Liang C, Wainberg MA. 2005. A HIV-1 minimal gag protein is superior to nucleocapsid at in vitro annealing and exhibits multimerization-induced inhibition of reverse transcription. *J Biol Chem* **280**: 17488–17496.
- Saadatmand J, Kleiman L. 2012. Aspects of HIV-1 assembly that promote primer tRNA^{Lys3} annealing to viral RNA. *Virus Res* **169**: 340–348.
- Saadatmand J, Guo F, Cen S, Niu M, Kleiman L. 2008. Interactions of reverse transcriptase sequences in Pol with Gag and LysRS in the HIV-1 tRNA^{Lys3} packaging/annealing complex. *Virology* **380**: 109–117.
- Shiba K, Stello T, Motegi H, Noda T, Musier-Forsyth K, Schimmel P. 1997. Human lysyl-tRNA synthetase accepts nucleotide 73 variants and rescues *Escherichia coli* double-defective mutant. *J Biol Chem* **272**: 22809–22816.
- Song M, Balakrishnan M, Gorelick RJ, Bambara RA. 2009. A succession of mechanisms stimulate efficient reconstituted HIV-1 minus strand strong stop DNA transfer. *Biochemistry* **48**: 1810–1819.
- Stello T, Hong M, Musier-Forsyth K. 1999. Efficient aminoacylation of tRNA^{Lys3} by human lysyl-tRNA synthetase is dependent on covalent continuity between the acceptor stem and the anticodon domain. *Nucleic Acids Res* **27**: 4823–4829.
- Stewart-Maynard KM, Cruceanu M, Wang F, Vo MN, Gorelick RJ, Williams MC, Rouzina I, Musier-Forsyth K. 2008. Retroviral nucleocapsid proteins display nonequivalent levels of nucleic acid chaperone activity. *J Virol* **82**: 10129–10142.
- Taylor JR. 1997. *An introduction to error analysis: The study of uncertainties in physical measurements*. University Science Books, Sausalito, CA.
- van Weringh A, Ragonnet-Cronin M, Pranckeviciene E, Pavon-Eternod M, Kleiman L, Xia X. 2011. HIV-1 modulates the tRNA pool to improve translation efficiency. *Mol Biol Evol* **28**: 1827–1834.
- Wakasugi K, Slike BM, Hood J, Otani A, Ewalt KL, Friedlander M, Cheresch DA, Schimmel P. 2002. A human aminoacyl-tRNA synthetase as a regulator of angiogenesis. *Proc Natl Acad Sci* **99**: 173–177.
- Watts JM, Dang KK, Gorelick RJ, Leonard CW, Bess JW Jr, Swanstrom R, Burch CL, Weeks KM. 2009. Architecture and secondary structure of an entire HIV-1 RNA genome. *Nature* **460**: 711–716.
- Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. *Antimicrob Agents Chemother* **46**: 1896–1905.
- Wilkinson KA, Gorelick RJ, Vasa SM, Guex N, Rein A, Mathews DH, Giddings MC, Weeks KM. 2008. High-throughput SHAPE analysis reveals structures in HIV-1 genomic RNA strongly conserved across distinct biological states. *PLoS Biol* **6**: e96.
- Zhu J, Korostelev A, Costantino DA, Donohue JP, Noller HF, Kieft JS. 2011. Crystal structures of complexes containing domains from two viral internal ribosome entry site (IRES) RNAs bound to the 70S ribosome. *Proc Natl Acad Sci* **108**: 1839–1844.

RNA

A PUBLICATION OF THE RNA SOCIETY

Molecular mimicry of human tRNA^{Lys} anti-codon domain by HIV-1 RNA genome facilitates tRNA primer annealing

Christopher P. Jones, Jenan Saadatmand, Lawrence Kleiman, et al.

RNA 2013 19: 219-229 originally published online December 21, 2012

Access the most recent version at doi:[10.1261/rna.036681.112](https://doi.org/10.1261/rna.036681.112)

Supplemental Material

<http://rnajournal.cshlp.org/content/suppl/2012/12/05/rna.036681.112.DC1>

References

This article cites 67 articles, 37 of which can be accessed free at:
<http://rnajournal.cshlp.org/content/19/2/219.full.html#ref-list-1>

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

To subscribe to *RNA* go to:

<http://rnajournal.cshlp.org/subscriptions>